180
Participants
Start Date
November 30, 2007
Primary Completion Date
July 31, 2010
Study Completion Date
August 31, 2010
Placebo [group P]
receive intravenous injection of 0.2 mL/kg of saline 0.9%L \[group P\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
0.2 mL/kg of aminophylline 10 mg/mL [group A2]
receive intravenous injection of 0.2 mL/kg of aminophylline 10 mg/mL \[group A2\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
0.2 mL/kg of aminophylline 15 mg/mL [group A3]
receive intravenous injection of 0.2 mL/kg of aminophylline 15 mg/mL \[group A3\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
0.2 mL/kg of aminophylline 20 mg/mL [group A4]
receive intravenous injection of 0.2 mL/kg of aminophylline 20 mg/mL \[group A4\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
0.2 mL/kg of aminophylline 25 mg/mL [group A5]
receive intravenous injection of 0.2 mL/kg of aminophylline 25 mg/mL \[group A5\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
Doxapram 1 mg/kg [group D]
receive intravenous injection of 0.2 mL/kg of doxapram 5 mg/mL \[group D\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
King Faisal University, Khobar
King Faisal University
OTHER